New Launch25 Aug 2025, 11:02 am
GSK Forays into Oncology in India with Jemperli and Zejula, Bringing Precision Therapies for Gynaecological Cancers
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd has announced the availability of Jemperli (dostarlimab) and Zejula (niraparib) in India. Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer. Zejula is the only once-daily oral PARP inhibitor approved in India as first line monotherapy maintenance for all biomarker types in advanced ovarian cancer. These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care.
Key Highlights
- GSK forays into Oncology in India with Jemperli and Zejula, bringing precision therapies for gynaecological cancers.
- Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of dMMR/MSI-H advanced or recurrent endometrial cancer in India.
- Zejula is the only once-daily oral PARP inhibitor approved in India as first line monotherapy maintenance for all biomarker types in advanced ovarian cancer.
- These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care.
- GSK is participating in ongoing oncology clinical trials aimed to extend the indication of dostarlimab to other cancers including non-small cell lung, head and neck and colorectal.